Shields William W, Pockros Paul J
Department of Gastroenterology and Hepatology, Naval Medical Center San Diego, San Diego, CA 92134, USA.
Clin Liver Dis. 2009 Aug;13(3):419-27. doi: 10.1016/j.cld.2009.05.006.
Ribavirin is ineffective against hepatitis C virus as mono-therapy but is critical in attaining both early virologic response and sustained virologic response when combined with pegylated interferon. Ribavirin has significant dose-limiting toxicities, the most important of which is hemolytic anemia. Taribavirin is a ribavirin pro-drug, which targets the liver and has less incidence of anemia, and it may be a promising alternative to ribavirin in the future.
利巴韦林单药治疗对丙型肝炎病毒无效，但与聚乙二醇化干扰素联合使用时，对于实现早期病毒学应答和持续病毒学应答至关重要。利巴韦林具有显著的剂量限制性毒性，其中最重要的是溶血性贫血。替拉瑞韦是一种利巴韦林前体药物，靶向肝脏，贫血发生率较低，未来可能是利巴韦林的一种有前景的替代药物。
